Manufacturing Expansion Opportunity to engage with Orchard on supply capacity planning and cGMP manufacturing services, leveraging their California expansion for lentiviral vector and cryopreserved cell therapy products to support ex vivo gene therapy programs.

Strategic Partnership Leverage Kyowa Kirin ownership to position co-development or co-commercialization discussions, aligning with Orchard’s pipeline priorities and potential access to global distribution channels via Kyowa Kirin network.

Global Access Capitalize on reimbursed access initiatives with Beneluxa and European centers by offering companion diagnostics, patient identification, and payer-ready commercialization support to accelerate market entry for Libmeldy and future therapies.

European Outreach Target collaborations for referral networks and treatment center access, building programs with Er-Kim and regional centers to streamline identification, referral, and treatment for early-onset MLD and related conditions.

Clinical and Data Services Provide data management, real-world evidence, and regulatory support services to facilitate trials and market access, aligning with Orchard’s gene therapy modalities and the broader ex vivo therapy ecosystem.